Earlier this year, The Lancet published the results of the LiGHT trial, comparing selective laser trabeculoplasty and eye drops to treat patients with open-angle glaucoma, which found SLT provided more robust IOP lowering while being a more cost-efficient first-line treatment.
Of 718 patients enrolled in the observer-masked, randomized controlled trial, 356 were treated with SLT and 362 were treated with eye drops. Researchers reported 91% of patients in the study returned the primary outcome questionnaire regarding health-related quality of life at 3 years assessed by EQ-5D scores.
At 36
Uncategorized